Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
about
Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Engineering Axl specific CAR and SynNotch receptor for cancer therapy.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.
P2860
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@en
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@nl
type
label
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@en
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@nl
prefLabel
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@en
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@nl
P2093
P2860
P921
P1433
P1476
Third-generation CD28/4-1BB ch ...... -label phase I trial protocol.
@en
P2093
Dan-Hong Wang
Guo-Liang Hu
Xiao-Yi Tang
P2860
P304
P356
10.1136/BMJOPEN-2016-013904
P577
2016-12-30T00:00:00Z